White FOx
The performance and speed of surface plasmon resonance with the ease-of-use of a dip-in fiber-optic biosensor.
FOx Biosystems
FOx Biosystems aims to revolutionize the life sciences industry and research market using its real-time, label-free analysis technology. The FOx technology is based on an innovative fiber-optic-based surface plasmon resonance biosensor technology. This enables the users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. FOx biosensor technology has several benefits compared to existing biomolecular analysis tools, including ease of use, speed, wide applicability and cost-effectiveness. FOx Biosystems sells instruments, sensor probes and services to improve biomolecular interaction analysis in life science research and industry. Fox Biosystems was founded in 2017 as a spin-off of the KU Leuven. In 2019 Fox Biosystems secured 4 million euros in capital with the Limburgse Investeringsmaatschappij LRM, the Gemma Frisius Fund, Heran Partners and several biotech investors.
FO-SPR Carboxyl probes
Dip-in probes with a generic surface chemistry that can couple a wide range of biomolecules
Browse Products by Field
FOx Biosystems aims to revolutionize the life sciences industry and research market using its real-time, label-free analysis technology. The FOx technology is based on an innovative fiber-optic-based surface plasmon resonance biosensor technology. This enables the users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. FOx biosensor technology has several benefits compared to existing biomolecular analysis tools, including ease of use, speed, wide applicability and cost-effectiveness. FOx Biosystems sells instruments, sensor probes and services to improve biomolecular interaction analysis in life science research and industry. Fox Biosystems was founded in 2017 as a spin-off of the KU Leuven. In 2019 Fox Biosystems secured 4 million euros in capital with the Limburgse Investeringsmaatschappij LRM, the Gemma Frisius Fund, Heran Partners and several biotech investors.